1. Recurrent pregnancy loss causes, controversies and treatment. Ed.: H.J.A. Carp. Informa UK Ltd, 2007.
2. Сидельникова В.М. Привычная потеря беременности. М.: Триада-Х, 2002.
3. Gruber CJ, Huber JC. The role of dydrogesterone in recurrent (habitual) abortion. J Steroid Biochem Mol Biol 2005; 97 (5): 426-30.
4. Walch K, Hefler L, Nagele F. Oral dydrogesterone treatment during the first trimester of pregnancy: the prevention of miscarriage study (PROMIS). A double-blind, prospectively randomized, placebo-controlled, parallel group trial. J Matern Fetal Neonatal Med 2005; 18 (4): 265–9.
5. Daya S et al. The Cochrane Database of Systematic Reviews: Reviews [Электронный ресурс]. John Wiley & Sons Ltd., 2007. – DOI: 10.1002/14651858.CD004830.
6. Dodd JM et al. Prenatal administration of progesterone for preventing preterm birth. The Cochrane Database of Systematic Reviews: Reviews [Электронный ресурс]. John Wiley & Sons Ltd., 2006. CD004947.
7. Сотникова Н.Ю., Посисеева Л.В., Анциферова Ю.С. Цитокиновый профиль женщин с угрозой невынашивания беременности и его модуляция препаратом Дюфастон. Журн. акуш. и женск. бол. 2006; 2: 42–6.
8. Сухих Г.Т., Ванько Л.В. Иммунология репродукции. М., 2003.
9. Empson M, Lassere M, Craig J, Scott J. The Cochrane Database of Systematic Reviews. The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 2006; 3.
10. De Marco P, Singh I, Weinstein A. Management of the antiphospholipid syndrome. Curr Rheum Rep 2006; 8 (2): 114–20.
11. Di Simone N, Meroni PL, D'Asta M. Pathogenic role of anti-beta-2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod Update 2007; 13 (2): 189-96.